Toward a cure for multiple myeloma within a decade - PubMed
14 hours ago
- #cure
- #multiple myeloma
- #MRD negativity
- Multiple myeloma (MM) is entering a transformative era with potential for cure within a decade.
- Early intervention in high-risk smoldering MM can delay progression and improve survival.
- Integrated risk models combining genomics, immune profiling, and AI are needed to refine treatment thresholds.
- Therapeutic goal is sustained minimal residual disease (MRD) negativity at a sensitivity of 10^-6, validated with functional imaging.
- Achieving 2-3 years of sustained MRD negativity predicts long-term progression-free survival; 5 years off therapy may approximate operational cure.
- Quadruplet induction, consolidation, and tailored maintenance regimens maximize response depth and durability.
- Priorities include standardized MRD and imaging assays, MRD-adapted clinical trials, and equitable global access.
- With decisive strategies, cure in MM is increasingly within reach.